155 related articles for article (PubMed ID: 34651095)
1. Durable Response to Larotrectinib in a Child With Histologic Diagnosis of Recurrent Disseminated Ependymoma Discovered to Harbor an
Mangum R; Reuther J; Bertrand KC; Chandramohan R; Kukreja MK; Paulino AC; Muzny D; Hu J; Gibbs RA; Curry DJ; Malbari F; Chintagumpala MM; Adesina AM; Fisher KE; Mack SC; Plon SE; Roy A; Parsons DW; Lin FY
JCO Precis Oncol; 2021; 5():. PubMed ID: 34651095
[No Abstract] [Full Text] [Related]
2. Discovery of a rare
Deland L; Keane S; Olsson Bontell T; Sjögren H; Fagman H; Øra I; De La Cuesta E; Tisell M; Nilsson JA; Ejeskär K; Sabel M; Abel F
Cancer Biol Ther; 2021 Mar; 22(3):184-195. PubMed ID: 33820494
[TBL] [Abstract][Full Text] [Related]
3. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
Farago AF; Demetri GD
Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
[TBL] [Abstract][Full Text] [Related]
4. [Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion].
Delaye M; Rodrigues M
Bull Cancer; 2020 Nov; 107(11):1085-1086. PubMed ID: 33169692
[No Abstract] [Full Text] [Related]
5. Mixed response and mechanisms of resistance to larotrectinib in metastatic carcinoma ex pleomorphic adenoma of the parotid harboring an NTRK2 fusion: A case report.
Pircher M; Briner HR; Bonomo M; Horcic M; Petrausch U; Helbling D; Winder T
Medicine (Baltimore); 2021 Jan; 100(4):e24463. PubMed ID: 33530256
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Maintenance Larotrectinib Therapy in 2 Children With NTRK Fusion-positive High-grade Cancers.
Carter-Febres M; Schneller N; Fair D; Solomon D; Perry A; Roy A; Linscott L; Alashari M; Kestle JR; Bruggers CS
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e987-e990. PubMed ID: 33093355
[TBL] [Abstract][Full Text] [Related]
7. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
Caldwell KJ; De La Cuesta E; Morin C; Pappo A; Helmig S
Pediatr Blood Cancer; 2020 Sep; 67(9):e28330. PubMed ID: 32452122
[TBL] [Abstract][Full Text] [Related]
8. Refractory infantile high-grade glioma containing TRK-fusion responds to larotrectinib.
Waters TW; Moore SA; Sato Y; Dlouhy BJ; Sato M
Pediatr Blood Cancer; 2021 May; 68(5):e28868. PubMed ID: 33403813
[No Abstract] [Full Text] [Related]
9. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
10. Genomic profiling in pediatric brain tumors.
Lau CC
Cancer J; 2005; 11(4):283-93. PubMed ID: 16197718
[No Abstract] [Full Text] [Related]
11. Loxo TRK inhibitor data wows oncologists.
Dolgin E
Nat Biotechnol; 2017 Aug; 35(8):694-695. PubMed ID: 28787403
[No Abstract] [Full Text] [Related]
12. NTRK fusion-positive cancers and TRK inhibitor therapy.
Cocco E; Scaltriti M; Drilon A
Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
[TBL] [Abstract][Full Text] [Related]
13. Larotrectinib imaging response in low-grade glioma.
Walter AW; Kandula VVR; Shah N
Pediatr Blood Cancer; 2020 Jan; 67(1):e28002. PubMed ID: 31544356
[No Abstract] [Full Text] [Related]
14. Larotrectinib in NTRK-Rearranged Solid Tumors
Wilson FH; Herbst RS
Biochemistry; 2019 Mar; 58(12):1555-1557. PubMed ID: 30865435
[No Abstract] [Full Text] [Related]
15. Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma.
Donson AM; Amani V; Warner EA; Griesinger AM; Witt DA; Levy JMM; Hoffman LM; Hankinson TC; Handler MH; Vibhakar R; Dorris K; Foreman NK
Mol Cancer Ther; 2018 Sep; 17(9):1984-1994. PubMed ID: 29925527
[TBL] [Abstract][Full Text] [Related]
16. Ependymomas in two sisters and a maternal male cousin with mosaicism with monosomy 22 in tumour.
Savard ML; Gilchrist DM
Pediatr Neurosci; 1989; 15(2):80-4. PubMed ID: 2699660
[TBL] [Abstract][Full Text] [Related]
17. Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.
Ziegler DS; Wong M; Mayoh C; Kumar A; Tsoli M; Mould E; Tyrrell V; Khuong-Quang DA; Pinese M; Gayevskiy V; Cohn RJ; Lau LMS; Reynolds M; Cox MC; Gifford A; Rodriguez M; Cowley MJ; Ekert PG; Marshall GM; Haber M
Br J Cancer; 2018 Sep; 119(6):693-696. PubMed ID: 30220707
[TBL] [Abstract][Full Text] [Related]
18. Activating NTRK2 and ALK receptor tyrosine kinase fusions extend the molecular spectrum of pleomorphic xanthoastrocytomas of early childhood: a diagnostic overlap with infant-type hemispheric glioma.
Lucas CG; Abdullaev Z; Bruggers CS; Mirchia K; Whipple NS; Alashari MM; Lowichik A; Cheshier S; Phillips JJ; Devine P; Solomon DA; Quezado M; Aldape KD; Perry A
Acta Neuropathol; 2022 Feb; 143(2):283-286. PubMed ID: 34910220
[No Abstract] [Full Text] [Related]
19. Predicting which children are at risk for ependymoma relapse.
Sowar K; Straessle J; Donson AM; Handler M; Foreman NK
J Neurooncol; 2006 May; 78(1):41-6. PubMed ID: 16575538
[TBL] [Abstract][Full Text] [Related]
20. A case report of a recurrent intracranial ependymoma treated with temozolomide in remission 10 years after completing chemotherapy.
Rehman S; Brock C; Newlands ES
Am J Clin Oncol; 2006 Feb; 29(1):106-7. PubMed ID: 16462515
[No Abstract] [Full Text] [Related]
[Next] [New Search]
